The Lancet Infectious Diseases
May 2015 Volume 15 Number 5 p487-614
Greatest effect of HPV vaccination from school-based programmes
David G Regan, Jane S Hocking
Published Online: 02 March 2015
Human papillomavirus (HPV) vaccination programmes have been in use in many countries since 2007 following licensing of the bivalent and quadrivalent HPV vaccines.1 Clinical trials have shown that HPV vaccines have more than 90% efficacy in preventing high-grade cervical lesions caused by human papillomavirus types 16 and 18,2,3 which are the two HPV types known to cause 70–80% of cervical cancers and large proportions of other anogenital and oropharyngeal cancers. The quadrivalent vaccine has shown similar efficacy in the prevention of anogenital warts caused by HPV types 6 and 11.